Show simple item record

dc.contributor.authorCorkery, John
dc.contributor.authorSchifano, Fabrizio
dc.date.accessioned2014-07-10T10:00:02Z
dc.date.available2014-07-10T10:00:02Z
dc.date.issued2013-12
dc.identifier.citationCorkery , J & Schifano , F 2013 , ' Factors Impacting on the Evolution and Characteristics of UK Deaths Involving‘Traditional’ and ‘New’ Stimulants. ' , Current Drug Abuse Reviews , vol. 6 , no. 4 , 16 , pp. 266-267 . https://doi.org/10.2174/187447370604140616124624
dc.identifier.issn1874-4737
dc.identifier.otherPURE: 7204732
dc.identifier.otherPURE UUID: e74c4857-7c6c-4f68-8ecc-19ee9c2d0de6
dc.identifier.urihttp://hdl.handle.net/2299/13909
dc.description.abstractIntroduction: This presentation outlines recent changes in UK drug indicators in respect of ‘traditional’ stimulants (amphetamine, cocaine, ecstasy) and how these may have influenced the ever-quickening emergence of ‘new’ stimulants (including cathinones, GHB/GBL, ketamine, piperazines) and its impact on drug-related death epidemiology. Methods: Trends in and associations between the following drug indicators are explored for the period 2005 – 2011: prevalence, availability (including seizures), price, purity, offending, treatment demand, hospital episodes, and deaths. Characteristics of deaths reported to the National Programme on Substance Abuse Deaths associated with ‘traditional’ and ‘new’ stimulants are examined to establish what similarities and differences exist. Results: Associations between drug indicators will be reported in terms of correlation co-efficients. Characteristics of victims are examined in terms of age, gender, ethnicity, history of drug use, employment, living arrangements. Characteristics of deaths are examined with respect to place of death, number and combinations of post-mortem drugs, role of substances in death; manner and cause(s). Conclusion: The findings are related to the existing knowledge based on ‘traditional’ stimulants. It is known that there are some similarities with the newer substances, but important differences are anticipated. These facts need to be taken into account by health professionals when faced with acute/chronic presentations in hospitals, and for those engaged in planning prevention and treatment services. Further research is needed on the most recent substances to emerge.en
dc.format.extent2
dc.language.isoeng
dc.relation.ispartofCurrent Drug Abuse Reviews
dc.titleFactors Impacting on the Evolution and Characteristics of UK Deaths Involving‘Traditional’ and ‘New’ Stimulants.en
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionCentre for Clinical Practice, Safe Medicines and Drug Misuse Research
dc.contributor.institutionPrescription and Illicit Drug Misuse
dc.contributor.institutionPublic Health
dc.contributor.institutionPatient and Medicines Safety
dc.description.statusPeer reviewed
dc.relation.school
dcterms.dateAccepted2013-12
rioxxterms.versionofrecordhttps://doi.org/10.2174/187447370604140616124624
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record